Angela Walsh - Virios Therapeutics SVP CFO
| VIRIDelisted Stock | USD 3.95 0.00 0.00% |
Insider
Angela Walsh is SVP CFO of Virios Therapeutics Llc
| Age | 57 |
| Phone | 866 620 8655 |
| Web | https://www.virios.com |
Angela Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Angela Walsh against Virios Therapeutics stock is an integral part of due diligence when investing in Virios Therapeutics. Angela Walsh insider activity provides valuable insight into whether Virios Therapeutics is net buyers or sellers over its current business cycle. Note, Virios Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Virios Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Angela Walsh over six months ago Acquisition by Angela Walsh of 2000 shares of Virios Therapeutics at 4.575 subject to Rule 16b-3 |
Virios Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6776) % which means that it has lost $0.6776 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1956) %, meaning that it created substantial loss on money invested by shareholders. Virios Therapeutics' management efficiency ratios could be used to measure how well Virios Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Virios Therapeutics Llc currently holds 358.55 K in liabilities. Virios Therapeutics Llc has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Virios Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| David MD | LMF Acquisition Opportunities | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Nandan BS | Immix Biopharma | 62 | |
| Caryl Baron | LMF Acquisition Opportunities | 57 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| DSc MSE | Immix Biopharma | 75 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| M FACP | LMF Acquisition Opportunities | 51 | |
| James Rolke | Revelation Biosciences | 55 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| MBA MD | Immix Biopharma | 49 | |
| Samuel MD | Altamira Therapeutics | 71 | |
Management Performance
| Return On Equity | -1.2 | |||
| Return On Asset | -0.68 |
Virios Therapeutics Llc Leadership Team
Elected by the shareholders, the Virios Therapeutics' board of directors comprises two types of representatives: Virios Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virios. The board's role is to monitor Virios Therapeutics' management team and ensure that shareholders' interests are well served. Virios Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virios Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Duncan, Chairman CEO | ||
| Carol Duffy, Chief Advisor | ||
| William MD, Founder Director | ||
| Ralph MPH, Senior Operations | ||
| Angela Walsh, SVP CFO |
Virios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virios Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 1.28 M | |||
| Shares Outstanding | 1.11 M | |||
| Shares Owned By Insiders | 6.74 % | |||
| Shares Owned By Institutions | 3.60 % | |||
| Number Of Shares Shorted | 469.93 K | |||
| Price To Book | 1.37 X | |||
| EBITDA | 150.9 K | |||
| Net Income | (5.3 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Virios Stock
If you are still planning to invest in Virios Therapeutics Llc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virios Therapeutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |